Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, Dispenzieri A, Kahanic SP, Thakuri MC, Reu FJ, Reynolds CM, Orlowski RZ, Barlogie B. Durie BGM, et al. Among authors: hoering a. Blood Cancer J. 2020 May 11;10(5):53. doi: 10.1038/s41408-020-0311-8. Blood Cancer J. 2020. PMID: 32393732 Free PMC article. Clinical Trial.
Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.
Usmani SZ, Sexton R, Ailawadhi S, Shah JJ, Valent J, Rosenzweig M, Lipe B, Zonder JA, Fredette S, Durie B, Hoering A, Bartlett B, Orlowski RZ. Usmani SZ, et al. Among authors: hoering a. Blood Cancer J. 2015 Aug 7;5(8):e334. doi: 10.1038/bcj.2015.62. Blood Cancer J. 2015. PMID: 26252787 Free PMC article. No abstract available.
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A. Durie BGM, et al. Among authors: hoering a. Lancet. 2017 Feb 4;389(10068):519-527. doi: 10.1016/S0140-6736(16)31594-X. Epub 2016 Dec 23. Lancet. 2017. PMID: 28017406 Free PMC article. Clinical Trial.
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.
Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, Turesson I, Lahuerta JJ, Attal M, Barlogie B, Lee JH, Kumar S, Lenhoff S, Morgan G, Rajkumar SV, Durie BGM, Moreau P. Usmani SZ, et al. Among authors: hoering a. Blood Cancer J. 2018 Nov 23;8(12):123. doi: 10.1038/s41408-018-0155-7. Blood Cancer J. 2018. PMID: 30470751 Free PMC article.
Long-term outcomes after autologous stem cell transplantation for multiple myeloma.
Nishimura KK, Barlogie B, van Rhee F, Zangari M, Walker BA, Rosenthal A, Schinke C, Thanendrarajan S, Davies FE, Hoering A, Morgan GJ. Nishimura KK, et al. Among authors: hoering a. Blood Adv. 2020 Jan 28;4(2):422-431. doi: 10.1182/bloodadvances.2019000524. Blood Adv. 2020. PMID: 31990333 Free PMC article.
Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma.
Ailawadhi S, Sexton R, Lentzsch S, Abidi MH, Voorhees PM, Cohen AD, Rohren EM, Heitner S, Kelly K, Mackler NJ, Baer DM, Hoering A, Durie B, Orlowski RZ. Ailawadhi S, et al. Among authors: hoering a. Clin Cancer Res. 2020 Aug 1;26(15):3969-3978. doi: 10.1158/1078-0432.CCR-19-1997. Epub 2020 Apr 16. Clin Cancer Res. 2020. PMID: 32299820 Free PMC article. Clinical Trial.
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Usmani SZ, Hoering A, Ailawadhi S, Sexton R, Lipe B, Hita SF, Valent J, Rosenzweig M, Zonder JA, Dhodapkar M, Callander N, Zimmerman T, Voorhees PM, Durie B, Rajkumar SV, Richardson PG, Orlowski RZ; SWOG1211 Trial Investigators. Usmani SZ, et al. Among authors: hoering a. Lancet Haematol. 2021 Jan;8(1):e45-e54. doi: 10.1016/S2352-3026(20)30354-9. Epub 2020 Dec 22. Lancet Haematol. 2021. PMID: 33357482 Free PMC article. Clinical Trial.
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
Nair B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Szymonifka J, Hoering A, Alsayed Y, Waheed S, Crowley J, Barlogie B. Nair B, et al. Among authors: hoering a. Blood. 2010 May 27;115(21):4168-73. doi: 10.1182/blood-2009-11-255620. Epub 2010 Feb 2. Blood. 2010. PMID: 20124509 Free PMC article. Clinical Trial.
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ, Waheed S, Chauhan N, Johann D, Abdallah AO, Muzaffar J, Petty N, Bailey C, Crowley J, van Rhee F, Barlogie B. Usmani SZ, et al. Among authors: hoering a. Blood. 2013 Jun 6;121(23):4753-7. doi: 10.1182/blood-2012-11-466961. Epub 2013 Apr 19. Blood. 2013. PMID: 23603914 Free PMC article.
94 results